EVMN

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-865.6K ExitQ1 2026 $866k -- $23.33
Paul Tudor Jones IITudor Investment $-547.0K ExitQ1 2026 $547k -- $23.33
Steven CohenPoint72 $841k36.6k shares AddQ1 2026 $252k $22.99 $23.33

News

businesswire.comEvommune Reports First Quarter 2026 Financial Results and Provides Business Highlightsbusinesswire.comMay 7

seekingalpha.comEvommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcriptseekingalpha.comApr 14

businesswire.comEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migrainebusinesswire.comApr 6

defenseworld.netCapricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMNdefenseworld.netApr 6

Trade EVMN

About Evommune, Inc.

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

CEO: Luis C. Pena
IPO Date: Nov 6, 2025

Market Data

Open: $21.00
High: $21.41
Low: $20.05
Volume: 480.5K
Avg Volume: 376.2K
52W High: $33.20
52W Low: $13.89

Valuation

Market Cap: $303M
Enterprise Value: $263M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-77M
Revenue: $13M
Net Income: $-69M
Cash: $44M
Debt: $2.1M

Events

EarningsOct 16

EPS est. -0.82